Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer.
Ditsch N, Vodermaier A, Hinke A, Burghardt S, Lenhard M, Löhrs B, Toth B, Von Koch F, Kahlert S, Bauerfeind I, Konecny GE, Loibl S, VON Minckwitz G, Untch M. Ditsch N, et al. Among authors: von koch f, von minckwitz g. Anticancer Res. 2012 Aug;32(8):3539-45. Anticancer Res. 2012. PMID: 22843943 Clinical Trial.
Thyroid function in breast cancer patients.
Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J, Toth B. Ditsch N, et al. Among authors: von koch f. Anticancer Res. 2010 May;30(5):1713-7. Anticancer Res. 2010. PMID: 20592366
Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.
Halfter K, Ditsch N, Kolberg HC, Fischer H, Hauzenberger T, von Koch FE, Bauerfeind I, von Minckwitz G, Funke I, Crispin A, Mayer B; Behalf of the SpheroNEO Study Group. Halfter K, et al. Among authors: von koch fe. BMC Cancer. 2015 Jul 15;15:519. doi: 10.1186/s12885-015-1491-7. BMC Cancer. 2015. PMID: 26169261 Free PMC article.
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE. Untch M, et al. Among authors: von koch f. J Clin Oncol. 2009 Jun 20;27(18):2938-45. doi: 10.1200/JCO.2008.20.3133. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364964 Clinical Trial.
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. Untch M, et al. Among authors: von koch f, von minckwitz g. Ann Oncol. 2011 Sep;22(9):1988-1998. doi: 10.1093/annonc/mdq709. Epub 2011 Mar 8. Ann Oncol. 2011. PMID: 21385882 Free article. Clinical Trial.
25 results